The impact on thirty day readmissions for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease admitted to an observation unit versus an inpatient medical unit: A retrospective observational study
CONCLUSION: Patients admitted for AECOPD with a history of PE, CHF, prior AECOPD admissions, and socioeconomic deprivation are at higher risk of readmission and should be prioritized for direct inpatient admission. Further prospective studies should be conducted to determine the clinical impact of this approach on readmission rates.PMID:38545901 | DOI:10.1177/14799731241242490 (Source: Chronic Respiratory Disease)
Source: Chronic Respiratory Disease - March 28, 2024 Category: Respiratory Medicine Authors: Jacob Bell Steven Lim Takahisa Mikami Jeeyune Bahk Stephen Argiro David Steiger Source Type: research
The impact on thirty day readmissions for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease admitted to an observation unit versus an inpatient medical unit: A retrospective observational study
CONCLUSION: Patients admitted for AECOPD with a history of PE, CHF, prior AECOPD admissions, and socioeconomic deprivation are at higher risk of readmission and should be prioritized for direct inpatient admission. Further prospective studies should be conducted to determine the clinical impact of this approach on readmission rates.PMID:38545901 | DOI:10.1177/14799731241242490 (Source: Respiratory Care)
Source: Respiratory Care - March 28, 2024 Category: Respiratory Medicine Authors: Jacob Bell Steven Lim Takahisa Mikami Jeeyune Bahk Stephen Argiro David Steiger Source Type: research
The impact on thirty day readmissions for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease admitted to an observation unit versus an inpatient medical unit: A retrospective observational study
CONCLUSION: Patients admitted for AECOPD with a history of PE, CHF, prior AECOPD admissions, and socioeconomic deprivation are at higher risk of readmission and should be prioritized for direct inpatient admission. Further prospective studies should be conducted to determine the clinical impact of this approach on readmission rates.PMID:38545901 | DOI:10.1177/14799731241242490 (Source: Chronic Respiratory Disease)
Source: Chronic Respiratory Disease - March 28, 2024 Category: Respiratory Medicine Authors: Jacob Bell Steven Lim Takahisa Mikami Jeeyune Bahk Stephen Argiro David Steiger Source Type: research
The impact on thirty day readmissions for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease admitted to an observation unit versus an inpatient medical unit: A retrospective observational study
CONCLUSION: Patients admitted for AECOPD with a history of PE, CHF, prior AECOPD admissions, and socioeconomic deprivation are at higher risk of readmission and should be prioritized for direct inpatient admission. Further prospective studies should be conducted to determine the clinical impact of this approach on readmission rates.PMID:38545901 | DOI:10.1177/14799731241242490 (Source: Respiratory Care)
Source: Respiratory Care - March 28, 2024 Category: Respiratory Medicine Authors: Jacob Bell Steven Lim Takahisa Mikami Jeeyune Bahk Stephen Argiro David Steiger Source Type: research
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
Conclusions: Biosimilar trastuzumab demonstrated similar safety and effectiveness to Herceptin. The findings can help improve confidence in and use of biosimilars and demonstrate the value of real-world evidence generation for supporting biosimilar implementations and reassessments.PMID:38534957 | DOI:10.3390/curroncol31030124 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Caroline Mu ñoz Xiaochen Tai Jessica Arias Andrea Eisen Munaza Chaudhry Scott Gavura Kelvin K W Chan Source Type: research
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
Conclusions: Biosimilar trastuzumab demonstrated similar safety and effectiveness to Herceptin. The findings can help improve confidence in and use of biosimilars and demonstrate the value of real-world evidence generation for supporting biosimilar implementations and reassessments.PMID:38534957 | DOI:10.3390/curroncol31030124 (Source: Cancer Control)
Source: Cancer Control - March 27, 2024 Category: Cancer & Oncology Authors: Caroline Mu ñoz Xiaochen Tai Jessica Arias Andrea Eisen Munaza Chaudhry Scott Gavura Kelvin K W Chan Source Type: research
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
Conclusions: Biosimilar trastuzumab demonstrated similar safety and effectiveness to Herceptin. The findings can help improve confidence in and use of biosimilars and demonstrate the value of real-world evidence generation for supporting biosimilar implementations and reassessments.PMID:38534957 | PMC:PMC10969053 | DOI:10.3390/curroncol31030124 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Caroline Mu ñoz Xiaochen Tai Jessica Arias Andrea Eisen Munaza Chaudhry Scott Gavura Kelvin K W Chan Source Type: research
